SCCR 31 Day 1. Debate on Definitions for Broadcasting & Cablecasting Treaty
DAY 1 (12/7/15) SCCR 31 Re Definitions
This is the text the member states are dicussing this afternoon:
For the purposes of this Treaty:(a) “signal” means an electronically generated carrier capable of transmitting a broadcast or
cablecast encrypted or not which carries the programmed output of a broadcasting organization.ALTERNATIVE A
(b) (1) “broadcasting” means the transmission by wireless means for reception by the
public of sounds or of images or of images and sounds or of the representations thereof, such
Continue ReadingSCCR 31 Check out the Text for Broadcasting & Cablecasting Treaty
At the close of the last meeting (June 29 to July 3, 2015), the WIPO Standing Committee on Copyright and Related Rights (SCCR) requested that the Chair prepare for its next session (December 7 to 11, 2015) a “consolidated text” with respect to 1) definitions, 2) object of protection, and 3) rights to be granted for the proposed treaty for the protection of broadcasting and cablecasting organizations.
KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
November 23, 2015
FYI: Contact: Andrew Goldman (andrew.goldman@keionline.org) or Zack Struver (zack.struver@keionline.org)
Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine for the treatment of the hepatitis C virus (HCV), and offers comments on the agreement.
23 November 2015: Opening statement of Asia and the Pacific Group at Tenth Session of WIPO Advisory Committee on Enforcement
The tenth session of the World Intellectual Property Organization’s (WIPO) Advisory Committee on Enforcement (ACE) meets from Monday, 23 November 2015 to Wednesday, 25 November 2015.
As noted by WIPO, the
Advisory Committee on Enforcement (ACE) was established by the 2002 WIPO General Assemblies with a mandate to carry out technical assistance and coordination in the field of enforcement (norm-setting is explicitly excluded from the mandate).
Seminars on Drug Pricing: Part 5 Kevin Outterson, Antibiotic Delinkage
UPDATED:
Here is a link to the recording of the seminar. Please see Professor Outterson’s slideshow for more detail and explanation.
Original
Continue ReadingTentative witness list for USITC hearing on Economic Impact of Trade Agreements
This is the tentative witness list for the November 17, 2015 United States International Trade Commission (USITC) hearing on “Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedure, 2016 Report. Inv. No.: 332-555”
The August 4, 2015 USITC notice about the hearing is here.
Dr. Margaret Chan: TPP may “close access to affordable medicines”
World Health Organization (WHO) Director-General Dr. Margaret Chan addressed civil society and policy-oriented “think tanks” on November 12, 2015, and “challenge[d]” them to “help with issues that keep me awake at night.” Specifically, she mentioned the problems with pharmaceutical patents, high drug prices as a barrier to access, and the current system of incentives for new drug innovation. Dr. Chan also raised concerns about the the TPP, which she said may raise drug prices and harm access to generics.
WTO Decision on Least Developed Country (LDC) Drug Patent Waiver
For Immediate Release
3 November 2015
Contact: Zack Struver, +1 (202) 332-2670 or zack.struver@keionline.orgGeneva — The World Trade Organization is poised to announce this Friday its approval of a limited 17-year extension of a 2001 waiver of obligations in the TRIPS Agreement, set to expire at the end of this year, the terms of which exempt Least Developed Countries (LDCs) from requirements to grant patents or related intellectual property rights on pharmaceutical products.
Harvard’s Oct. 23, 2015 forum on “Drug Pricing: Public Health Implications”
On October 23, 2015, the Harvard T.H. Chan School of Public Health hosted a forum titled “Drug Pricing: Public Health Implications,” that was moderated by Caroline Humer, a Reuters healthcare correspondent. The forum featured a panel of four individuals who work on drug pricing:
- Steven Pearson, President of the Institute for Clinical and Economic Review and Lecturer at Harvard Medical School
Support for the Delinkage of the Costs of R&D and the Price of Medicines
The concept of delinkage refers to an model of incentivizing innovation in pharmaceutical research and development wherein the price of a medical technology is not linked to the cost of R&D. The application of delinkage in the medical technologies market has been gaining broad based support from NGOs, IGOs, and governments. Below are a selection of public statements, resolutions, bills, and papers that call for the need for delinkage in ensuring global access to medicines.
Endorsements by Governments
European Union:
Continue Reading